Elicio Therapeutics tumbles as pancreatic cancer vaccine misses main goal of trial

Elicio Therapeutics

15/06/2026 13:08

** Shares of biotech firm Elicio Therapeutics ELTX.O fall 50% to $7.43 premarket
** Company says its experimental vaccine, ELI-002 7P, being tested in pancreatic cancer patients failed to prevent the return of the disease
    ** ELTX says mid-stage study tested 144 patients after surgery and standard treatment
** Says subgroup with fully removed tumors saw 35% lower risk of cancer returning
** Pancreatic cancer is hard to treat as it is often diagnosed late and responds poorly to existing therapies
    ** Company says vaccine triggered immune response linked to better outcomes
** Plans late-stage study focused on subgroup and longer treatment - ELTX
** As of last close, stock up ~87% YTD
 
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))